THE BOTTOM LINE
- Major M&A Deals Face Higher Hurdles: The EU’s General Court has shown it will block merger approvals if the proposed fixes (“remedies”) are not commercially and logistically sound, creating significant uncertainty for large-scale consolidation plans.
- Intense Scrutiny on Divestment Packages: Companies seeking merger clearance must now prove that any divested assets can be immediately and effectively operated by a competitor. Theoretical solutions that ignore practical barriers like traffic rights or certifications will be rejected.
- Increased Risk for Third-Party Challengers: This ruling empowers competitors to successfully challenge merger approvals they believe are based on weak or impractical remedies, adding a new layer of strategic risk to M&A.
THE DETAILS
The European Commission had initially green-lit the high-profile acquisition of Asiana by Korean Air, a deal set to create a dominant player in the air transport market between Europe and South Korea. Recognizing the potential harm to competition, particularly on cargo routes, the Commission’s approval was conditional. Korean Air committed to a “remedy package,” which involved divesting a combination of aircraft, personnel, and airport slots to a rival airline. This was intended to create a new, viable competitor on the affected routes, thereby preserving market competition.
However, the EU’s General Court has now annulled that approval, siding with a challenge brought by competitor Air France-KLM. The Court found the Commission made a “manifest error of assessment” by accepting a remedy that was not guaranteed to work in practice. The core of the judgment focused on the cargo business. The Court pointed out that the Commission failed to properly verify whether the airline taking over the divested assets (the “remedy taker”) would actually be able to secure the necessary traffic rights to operate the routes. Without these rights, the entire remedy package would be useless.
This decision sends a clear and forceful message to the C-suite and their legal advisors: when proposing remedies to fix a competition problem, “good enough” on paper is no longer good enough. The Court is insisting on a high degree of certainty. The European Commission, and by extension the merging parties, must now rigorously demonstrate that a proposed remedy is not just theoretically plausible but practically executable from day one. This raises the bar for due diligence in M&A planning, requiring a deeper analysis of the regulatory and operational realities facing any potential buyer of divested assets.
SOURCE
General Court of the European Union
